Date:7/31/2012

on agreement, whether Optimer will be able to realize expected benefits under its co-promotion agreement with Cubist and its collaboration agreements with Astellas, the fact that past results may not be predictive of future results or performance, the possibility of alternative means of preventing or treating CDAD impacting adoption and sales of DIFICID, Optimer's ability, through its third party manufacturers and logistics providers, to maintain a sufficient supply of DIFICID to meet demand, DIFICID's ability to compete against lower-priced generic products and other risks detailed in Optimer's filings with the Securities and Exchange Commission.  Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law.Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
(619) 849-6005

OPTIMER and DIFICID are trademarks of Optimer Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.Optimer Pharmaceuticals, Inc.Consolidated Statements of Operations(unaudited) Three Months Ended  Six Months Ended  June 30,  June 30, 2012201120122011Revenues:Product sales, net

$   15,232,087$
-$  29,612,628$
-Collaboration

34,525,485-34,525,48569,165,000Other

-33,2942,106144,933Total revenues

49,757,57233,29464,140,21969,309,933Cost and expenses:Cost of product sales

2,269,331-4,553,591-Cost of contract revenue

1,744,182-1,744,1824,273,532Research and development

11,557,21710,290,76022,625,18418,668,769Selling , general and administrative

28,856,92914,760,72354,379,21126,566,998Co-promotion expenses with Cubist

5,001,583-1
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related biology technology :

1. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2. Global Biopharmaceuticals Market 2011-2015
3. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
4. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
6. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
8. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
9. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference